Kir6.2 Deficiency Promotes Mesencephalic Neural Precursor Cell Differentiation via Regulating miR-133b/GDNF in a Parkinson's Disease Mouse Model

Mol Neurobiol. 2018 Nov;55(11):8550-8562. doi: 10.1007/s12035-018-1005-0. Epub 2018 Mar 21.

Abstract

The loss of dopaminergic (DA) neurons in the substantia nigra (SN) is a major feature in the pathology of Parkinson's disease (PD). Using neural stem or progenitor cells (NSC/NPCs), the prospect of replacing the missing or damaged DA neurons is very attractive for PD therapy. However, little is known about the endogenous mechanisms and molecular pathways regulating the NSC/NPC proliferation and differentiation in the development of PD. Herein, using Kir6.2 knockout (Kir6.2-/-) mice, we observed that genetic deficiency of Kir6.2 exacerbated the loss of SN DA neurons relatively early in a chronic MPTP/probenecid (MPTP/p) injection course, but rescued the damage of neurons 7 days after the last MPTP/p injection. Meanwhile, we found that Kir6.2 knockout predominantly increased the differentiation of nuclear receptor-related 1 (Nurr1+) precursors to DA neurons, indicating that Kir6.2 deficiency could activate an endogenous self-repair process. Furthermore, we demonstrated in vivo and in vitro that lack of Kir6.2 promoted neuronal differentiation via inhibiting the downregulation of glia cell line-derived neurotrophic factor (GDNF), which negatively related to the level of microRNA-133b. Notably, we revealed that Gdnf is a target gene of miR-133b and transfection of miR-133b could attenuate the enhancement of neural precursor differentiation induced by Kir6.2 deficiency. Collectively, we clarify for the first time that Kir6.2/K-ATP channel functions as a novel endogenous negative regulator of NPC differentiation, and provide a promising neuroprotective target for PD therapeutics.

Keywords: Adult neurogenesis; Differentiation; Kir6.2/K-ATP; Nurr1+ precursors; Parkinson’s disease; miR-133b.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Cell Differentiation*
  • Cell Proliferation
  • Disease Models, Animal
  • Dopaminergic Neurons / metabolism
  • Down-Regulation / genetics
  • Glial Cell Line-Derived Neurotrophic Factor / genetics*
  • Glial Cell Line-Derived Neurotrophic Factor / metabolism
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Homeodomain Proteins / metabolism
  • Mesencephalon / pathology*
  • Mice, Inbred C57BL
  • Mice, Knockout
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Models, Biological
  • Neural Stem Cells / metabolism*
  • Nuclear Receptor Subfamily 4, Group A, Member 2 / metabolism
  • Parkinson Disease / genetics*
  • Parkinson Disease / pathology*
  • Phosphorylation
  • Potassium Channels, Inwardly Rectifying / deficiency*
  • Potassium Channels, Inwardly Rectifying / metabolism
  • Probenecid
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Transcription Factors / metabolism
  • alpha-Synuclein / metabolism
  • beta Catenin / metabolism

Substances

  • Glial Cell Line-Derived Neurotrophic Factor
  • Homeodomain Proteins
  • Kir6.2 channel
  • MicroRNAs
  • Mirn133 microRNA, mouse
  • Nr4a2 protein, mouse
  • Nuclear Receptor Subfamily 4, Group A, Member 2
  • Potassium Channels, Inwardly Rectifying
  • Proto-Oncogene Proteins c-bcl-2
  • Transcription Factors
  • alpha-Synuclein
  • beta Catenin
  • homeobox protein PITX3
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Glycogen Synthase Kinase 3 beta
  • Probenecid